Jane Street’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Jane Street’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-28,000	Closed	-$118K	–	10052
2023 Q1	$118K	Sell	28,000 -37,200	-57%	-$193K	﹤0.01%	8142
2022 Q4	$392K	Sell	65,200 -71,900	-52%	-$392K	﹤0.01%	6564
2022 Q3	$798K	Sell	137,100 -98,700	-42%	-$615K	﹤0.01%	5842
2022 Q2	$1.41M	Buy	235,800 +164,700	+232%	+$843K	﹤0.01%	4836
2022 Q1	$332K	Buy	71,100 +13,000	+22%	+$38.8K	﹤0.01%	8248
2021 Q4	$144K	Buy	+58,100	New	+$142K	﹤0.01%	9031

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Jane Street's CTIC Position: Q2 2023 in Review

Jane Street sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 329,771 shares — an estimated $1.39M sold.

Jane Street first reported a position in CTIC in Q2 2013 and held it in 27 quarters. The position peaked at $3.63M in Q2 2015. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Jane Street reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Jane Street sold 329,771 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $1.39M.
Jane Street first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 27 quarters.
Jane Street's CTI BioPharma Corp. (DE) Common Stock position peaked at $3.63M in Q2 2015.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.